Table 4.
Number of | Incidence of events (%) | |||||||
Outcome and comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
Patient with any adverse event | ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 55 | 48 | 1.08 (1.04–1.13)a | 15 (11–21)c |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 32 | 32 | 1.0 (0.84–1.2) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 3 | 769 | 48 | 49 | 0.97 (0.84–1.1) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,615 | 45 | 50 | 0.92 (0.89–0.95)a | 18 (14–23)b |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,711 | 53 | 60 | 0.96 (0.94–0.98)a | 15 (13–18)b |
Celecoxib (any dose) v any active | Any | Any active comparator | 24 | 33,400 | 53 | 59 | 0.96 (0.94–0.98)a | 17 (14–21)b |
Patient with any treatment-related adverse event | ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 9.5 | 8.1 | 1.22 (1.06–1.40)a | 71 (39–450)c |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 3 | 1,056 | 9.0 | 8.8 | 1.04 (0.71–1.5) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 4 | 1,579 | 6.6 | 9.0 | 0.74 (0.53–1.04) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,615 | 13.0 | 17.3 | 0.77 (0.72–0.82)a | 24 (19–31)b |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 19 | 23,743 | 12.7 | 17.3 | 0.77 (0.72–0.82)a | 22 (18–27)b |
Celecoxib (any dose) v any active | Any | Any active comparator | 24 | 26,242 | 12.3 | 16.2 | 0.78 (0.73–0.83)a | 26 (21–33)b |
Patient with any serious adverse event | ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 1.0 | 1.4 | 0.67 (0.46–0.98)a | 280 (120–790)b |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 0.5 | 0.6 | 0.76 (0.14–4.1) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 2.3 | 2.1 | 1.1 (0.68–1.9) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,612 | 2.5 | 2.6 | 0.91 (0.77–1.08) | |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,708 | 3.3 | 3.6 | 1.02 (0.91–1.15) | |
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,299 | 3.2 | 3.4 | 1.02 (0.91–1.15) | |
Patient with any gastrointestinal adverse event | ||||||||
Celecoxib v placebo | Any | Placebo | 17 | 9,512 | 26.0 | 19.0 | 1.2 (1.1–1.4)a | 14 (12–19)c |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 12.0 | 11.0 | 1.1 (0.8–1.6) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 16.0 | 18.0 | 0.87 (0.74–1.03) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 18 | 30,043 | 26.0 | 34.0 | 0.84 (0.81–0.87)a | 12 (10–13)b |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 18 | 31,171 | 26.0 | 34.0 | 0.84 (0.81–0.87)a | 12 (10–13)b |
Celecoxib (any dose) v any active | Any | Any active comparator | 24 | 34,762 | 26.0 | 32.0 | 0.85 (0.82–0.88)a | 14 (12–16)b |
aRelative risk: bold indicates statistically significant difference. bNNTp (number-needed-to-treat to prevent one event) is indicated by bold. cNNH (number-needed-to-treat to harm one patient). CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug.